4D Molecular Therapeutics... (FDMT)
4.86
0.10 (2.10%)
At close: Jan 14, 2025, 3:59 PM
4.75
-2.16%
After-hours Jan 14, 2025, 04:05 PM EST
undefined% (undefined)
| Bid | 4.71 |
| Market Cap | 224.67M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.85 |
| PE Ratio (ttm) | -1.71 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.69 |
| Volume | 547,624 |
| Avg. Volume (20D) | 892,793 |
| Open | 4.83 |
| Previous Close | 4.76 |
| Day's Range | 4.80 - 5.08 |
| 52-Week Range | 4.67 - 36.25 |
| Beta | undefined |
About FDMT
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 11, 2020
Employees 147
Stock Exchange NASDAQ
Ticker Symbol FDMT
Analyst Forecast
According to 11 analyst ratings, the average rating for FDMT stock is "Buy." The 12-month stock price forecast is $39.5, which is an increase of 712.76% from the latest price.
Buy 81.82%
Hold 9.09%
Sell 9.09%
Next Earnings Release
4D Molecular Therapeutics Inc. is scheduled to release its earnings on Feb 27, 2025,
during market hours.
Analysts project revenue of $2.20M, reflecting a -13.04K% YoY shrinking and earnings per share of -0.83, making a 7.79% increase YoY.
Analysts project revenue of $2.20M, reflecting a -13.04K% YoY shrinking and earnings per share of -0.83, making a 7.79% increase YoY.
2 days ago ·
Source
-13.77%
4D Molecular Therapeutics shares are trading lower...
Unlock content with
Pro Subscription
3 months ago ·
Source
-19.74%
4D Molecular Therapeutics shares are trading lower. Leerink Partners lowered its price target on the stock from $40 to $36.
